Simufilam hydrochloride is a Small Molecule owned by Cassava Sciences, and is involved in 10 clinical trials, of which 4 were completed, and 6 are ongoing.

Sumifilam acts as filamin A inhibitor. Filamin A is involved in amyloid deposits and tau phosphorylation. The drug candidate by binding to filamin A with high affinity prevents amyloid beta (42) toxic cascade, thereby reducing the phospho-tau and Abeta aggregates and reducing the dysfunction of a7nAChR.

The revenue for Simufilam hydrochloride is expected to reach a total of $1.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Simufilam hydrochloride NPV Report.

Simufilam hydrochloride is originated and owned by Cassava Sciences.

Simufilam hydrochloride Overview

Simufilam (formerly known as sumifilam) is under development for the treatment of Alzheimer’s disease. The drug candidate is administered through oral route. The drug candidate is a small molecule. It targets scaffolding protein filamin A (FLNA).

Cassava Sciences Overview

Cassava Sciences, formerly Pain Therapeutics, is a clinical-stage biopharmaceutical company that develops drugs for the treatment of neuroinflammation and neurodegenerative diseases, with a special focus on Alzheimer’s disease. The company’s lead product candidate Simufilam is a small molecule being developed in phase 3 clinical trials for treatment of Alzheimer’s disease. The clinical trials are conducted in phase3 studies such as Rethink-ALZ and Refocus-ALZ. It is also investigating SavaDx, a blood-based diagnostic for detection of Alzheimer’s disease. Major investor include national institute of health of health (NIH), National Institute on Aging (NIA). Cassava Sciences is headquartered in Austin, Texas, the US.

The operating loss of the company was US$32.9 million in FY2021, compared to an operating loss of US$6.5 million in FY2020. The net loss of the company was US$32.4 million in FY2021, compared to a net loss of US$6.3 million in FY2020.

Quick View – Simufilam hydrochloride

Report Segments
  • Innovator
Drug Name
  • Simufilam hydrochloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.